A value-based budget impact model for dronedarone compared with other rhythm control strategies
Journal of Comparative Effectiveness Research · 2023
DOI: 10.57264/cer-2022-0196 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Comparative Effectiveness Research, 2023. Verfasst von Jennifer Ken-Opurum und 7 weiteren Autor:innen. Beteiligte Einrichtung: Axtria Inc., Decision Science, Health Economics and Outcomes Research / Real-World Evidence, Berkley Heights, NJ 07922, USA. Hauptthemen laut MEDLINE: Amiodarone, Atrial Fibrillation. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Sanofi.
Abstract (Originalsprache)
Aim
The budgetary consequences of increasing dronedarone utilization for treatment of atrial fibrillation were evaluated from a US payer perspective. Materials & methods: A budget impact model over a 5-year time horizon was developed, including drug-related costs and risks for long-term clinical outcomes (LTCOs). Treatments included antiarrhythmic drugs (AADs; dronedarone, amiodarone, sotalol, propafenone, dofetilide, flecainide), rate control medications, and ablation. Direct comparisons and temporal and non-temporal combination scenarios investigating treatment order were analyzed as costs per patient per month (PPPM).
Results
By projected year 5, costs PPPM for dronedarone versus other AADs decreased by $37.69 due to fewer LTCOs, treatment with dronedarone versus ablation or rate control medications + ablation resulted in cost savings ($359.94 and $370.54, respectively), and AADs placed before ablation decreased PPPM costs by $242 compared with ablation before AADs.
Conclusion
Increased dronedarone utilization demonstrated incremental cost reductions over time.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Axtria Inc., Decision Science, Health Economics and Outcomes Research / Real-World Evidence, Berkley Heights, NJ 07922, USA.
- Sanofi US, US General Medicines, Bridgewater, NJ 08807, USA.
Förderung
- Sanofi
Zitieren
APA
Ken-Opurum, J., Srinivas, S. S., Vadagam, P., Faith, L., Park, S., Charland, S., Revel, A., & Preblick, R. (2023). A value-based budget impact model for dronedarone compared with other rhythm control strategies. Journal of Comparative Effectiveness Research. https://doi.org/10.57264/cer-2022-0196
Vancouver
Ken-Opurum J, Srinivas SS, Vadagam P, Faith L, Park S, Charland S, et al. A value-based budget impact model for dronedarone compared with other rhythm control strategies. Journal of Comparative Effectiveness Research. 2023. doi:10.57264/cer-2022-0196
BibTeX
@article{KenOpurum2023,
author = {Ken-Opurum, Jennifer and Srinivas, Sesha Ss and Vadagam, Pratyusha and Faith, Lang and Park, Seojin and Charland, Scott and Revel, Andrew and Preblick, Ronald},
title = {A value-based budget impact model for dronedarone compared with other rhythm control strategies},
journal = {Journal of Comparative Effectiveness Research},
year = {2023},
doi = {10.57264/cer-2022-0196}
}
EUVIMED